5a6i › Citations

Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity.

<div class='caption-title'>Tolcapone and tafamidis effects over WT, V122I-TTR and A25T-TTR aggregation and stability.</div>
<div class='caption-title'>Interaction of TTR with tolcapone assessed by ITC.</div>
<div class='caption-title'>Crystal structures of WT-TTR/ligand and V122I-TTR/ligand complexes.</div>
Sant'Anna R, Gallego P, Robinson LZ, Pereira-Henriques A, Ferreira N, Pinheiro F, Esperante S, Pallares I, Huertas O, Almeida MR, Reixach N, Insa R, Velazquez-Campoy A, Reverter D, Reig N, Ventura S
OpenAccess logo Nat Commun 7 10787 (2016)
Cited: 75 times
EuropePMC logo PMID: 26902880

Abstract

Transthyretin (TTR) is a plasma homotetrameric protein implicated in fatal systemic amyloidoses. TTR tetramer dissociation precedes pathological TTR aggregation. Native state stabilizers are promising drugs to treat TTR amyloidoses. Here we repurpose tolcapone, an FDA-approved molecule for Parkinson's disease, as a potent TTR aggregation inhibitor. Tolcapone binds specifically to TTR in human plasma, stabilizes the native tetramer in vivo in mice and humans and inhibits TTR cytotoxicity. Crystal structures of tolcapone bound to wild-type TTR and to the V122I cardiomyopathy-associated variant show that it docks better into the TTR T4 pocket than tafamidis, so far the only drug on the market to treat TTR amyloidoses. These data indicate that tolcapone, already in clinical trials for familial amyloid polyneuropathy, is a strong candidate for therapeutic intervention in these diseases, including those affecting the central nervous system, for which no small-molecule therapy exists.

Articles - 5a6i mentioned but not cited (2)

  1. Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity. Sant'Anna R, Gallego P, Robinson LZ, Pereira-Henriques A, Ferreira N, Pinheiro F, Esperante S, Pallares I, Huertas O, Almeida MR, Reixach N, Insa R, Velazquez-Campoy A, Reverter D, Reig N, Ventura S. Nat Commun 7 10787 (2016)
  2. Structural and dynamics evidence for scaffold asymmetric flexibility of the human transthyretin tetramer. Zanotti G, Vallese F, Ferrari A, Menozzi I, Saldaño TE, Berto P, Fernandez-Alberti S, Berni R. PLoS One 12 e0187716 (2017)


Reviews citing this publication (34)

  1. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. J Am Coll Cardiol 73 2872-2891 (2019)
  2. Review of Drug Repositioning Approaches and Resources. Xue H, Li J, Xie H, Wang Y. Int J Biol Sci 14 1232-1244 (2018)
  3. Stabilization of protein-protein interactions in drug discovery. Andrei SA, Sijbesma E, Hann M, Davis J, O'Mahony G, Perry MWD, Karawajczyk A, Eickhoff J, Brunsveld L, Doveston RG, Milroy LG, Ottmann C. Expert Opin Drug Discov 12 925-940 (2017)
  4. One mutation, two distinct disease variants: unravelling the impact of transthyretin amyloid fibril composition. Suhr OB, Lundgren E, Westermark P. J Intern Med 281 337-347 (2017)
  5. The Prion-Like Spreading of Alpha-Synuclein in Parkinson's Disease: Update on Models and Hypotheses. Jan A, Gonçalves NP, Vaegter CB, Jensen PH, Ferreira N. Int J Mol Sci 22 8338 (2021)
  6. Visualizing and trapping transient oligomers in amyloid assembly pathways. Cawood EE, Karamanos TK, Wilson AJ, Radford SE. Biophys Chem 268 106505 (2021)
  7. Pathophysiology and Therapeutic Approaches to Cardiac Amyloidosis. Griffin JM, Rosenblum H, Maurer MS. Circ Res 128 1554-1575 (2021)
  8. Systemic amyloidosis: novel therapies and role of biomarkers. Nuvolone M, Merlini G. Nephrol Dial Transplant 32 770-780 (2017)
  9. Transthyretin Cardiac Amyloidosis in Older Americans. Brunjes DL, Castano A, Clemons A, Rubin J, Maurer MS. J Card Fail 22 996-1003 (2016)
  10. Protein-Remodeling Factors As Potential Therapeutics for Neurodegenerative Disease. Jackrel ME, Shorter J. Front Neurosci 11 99 (2017)
  11. Amyloidosis-the Diagnosis and Treatment of an Underdiagnosed Disease. Ihne S, Morbach C, Sommer C, Geier A, Knop S, Störk S. Dtsch Arztebl Int 117 159-166 (2020)
  12. Exploring the new horizons of drug repurposing: A vital tool for turning hard work into smart work. Kumar R, Harilal S, Gupta SV, Jose J, Thomas Parambi DG, Uddin MS, Shah MA, Mathew B. Eur J Med Chem 182 111602 (2019)
  13. Advances in the Treatment of Cardiac Amyloidosis. Macedo AVS, Schwartzmann PV, de Gusmão BM, Melo MDT, Coelho-Filho OR. Curr Treat Options Oncol 21 36 (2020)
  14. Emerging Therapeutics for the Treatment of Light Chain and Transthyretin Amyloidosis. Zhang KW, Stockerl-Goldstein KE, Lenihan DJ. JACC Basic Transl Sci 4 438-448 (2019)
  15. Understanding and predicting protein misfolding and aggregation: Insights from proteomics. Pallarès I, Ventura S. Proteomics 16 2570-2581 (2016)
  16. Novel pharmacotherapies for cardiac amyloidosis. Alexander KM, Singh A, Falk RH. Pharmacol Ther 180 129-138 (2017)
  17. Molecular Mechanisms of Cardiac Amyloidosis. Saito Y, Nakamura K, Ito H. Int J Mol Sci 23 25 (2021)
  18. Treating Protein Misfolding Diseases: Therapeutic Successes Against Systemic Amyloidoses. Nevone A, Merlini G, Nuvolone M. Front Pharmacol 11 1024 (2020)
  19. Modulation of the Mechanisms Driving Transthyretin Amyloidosis. Bezerra F, Saraiva MJ, Almeida MR. Front Mol Neurosci 13 592644 (2020)
  20. Emerging modes-of-action in drug discovery. Valeur E, Narjes F, Ottmann C, Plowright AT. Medchemcomm 10 1550-1568 (2019)
  21. Emerging therapeutic targets currently under investigation for the treatment of systemic amyloidosis. Nuvolone M, Merlini G. Expert Opin Ther Targets 21 1095-1110 (2017)
  22. Molecular and Clinical Aspects of Protein Aggregation Assays in Neurodegenerative Diseases. Villar-Piqué A, Schmitz M, Candelise N, Ventura S, Llorens F, Zerr I. Mol Neurobiol 55 7588-7605 (2018)
  23. Current and Emerging Therapies for Hereditary Transthyretin Amyloidosis: Strides Towards a Brighter Future. Obici L, Mussinelli R. Neurotherapeutics 18 2286-2302 (2021)
  24. Review on the Structures and Activities of Transthyretin Amyloidogenesis Inhibitors. Guo X, Liu Z, Zheng Y, Li Y, Li L, Liu H, Chen Z, Wu L. Drug Des Devel Ther 14 1057-1081 (2020)
  25. Are we creating a new phenotype? Physiological barriers and ethical considerations in the treatment of hereditary transthyretin-amyloidosis. Dohrn MF, Medina J, Olaciregui Dague KR, Hund E. Neurol Res Pract 3 57 (2021)
  26. Causally treatable, hereditary neuropathies in Fabry's disease, transthyretin-related familial amyloidosis, and Pompe's disease. Finsterer J, Wanschitz J, Quasthoff S, Iglseder S, Löscher W, Grisold W. Acta Neurol Scand 136 558-569 (2017)
  27. Changing paradigm in the treatment of amyloidosis: From disease-modifying drugs to anti-fibril therapy. Quarta CC, Fontana M, Damy T, Catini J, Simoneau D, Mercuri M, Garcia-Pavia P, Maurer MS, Palladini G. Front Cardiovasc Med 9 1073503 (2022)
  28. Chemical Kinetic Strategies for High-Throughput Screening of Protein Aggregation Modulators. Sárkány Z, Rocha F, Damas AM, Macedo-Ribeiro S, Martins PM. Chem Asian J 14 500-508 (2019)
  29. Narrative review of pharmacotherapy for transthyretin cardiac amyloid. Cruz Rodriguez JB, Tallaj JA. Ann Transl Med 9 519 (2021)
  30. Recent advances in the diagnosis and management of amyloid cardiomyopathy. Nijst P, Tang WW. Fac Rev 10 31 (2021)
  31. Targeted treatments of AL and ATTR amyloidosis. Chandrashekar P, Desai AK, Trachtenberg BH. Heart Fail Rev 27 1587-1603 (2022)
  32. Transthyretin Stabilizers and Seeding Inhibitors as Therapies for Amyloid Transthyretin Cardiomyopathy. Morfino P, Aimo A, Vergaro G, Sanguinetti C, Castiglione V, Franzini M, Perrone MA, Emdin M. Pharmaceutics 15 1129 (2023)
  33. Oral Therapy for the Treatment of Transthyretin-Related Amyloid Cardiomyopathy. Nuvolone M, Girelli M, Merlini G. Int J Mol Sci 23 16145 (2022)
  34. Recent Progress in the Development and Clinical Application of New Drugs for Transthyretin Cardiac Amyloidosis. Zhou J, Li Y, Geng J, Zhou H, Liu L, Peng X. J Cardiovasc Pharmacol 82 427-437 (2023)

Articles citing this publication (39)



Quick links